When can an off-label drug be the appropriate comparator therapy?
This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural
Category: News and updates
G-BA assesses method of allogeneic SCT in ALL, AML and NHL
Did you know that some hospital methods are not covered by SHI funds? In Germany, non-drug interventions are assessed as methods. Methods
The process of method assessments in Germany
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,
New rapid report by IQWiG
The IQWiG not only examines the benefits and harms of medical interventions for early benefit assessments but also produces independent, evidence-based reports
Negotiated reimbursement price applicable 12 months after launch
The IQWiG methods will be updated again
The IQWiG has just published draft version 6.1 of its “General methods”. The General Methods describe the work procedures of the IQWiG,
The G-BA starts the development of a new DMP for obesity
This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
Reimbursement in Germany in real practice
We do often talk about pharmaceutical companies aiming to achieve “reimbursement” for the products, but what does that actually mean in real
NUB method assessments to become faster
Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced
The early benefit assessment – 7 new laws since AMNOG
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called